Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing.
Saved in:
| Title: | Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing. |
|---|---|
| Authors: | Taube JM; Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University SOM, Baltimore, Maryland, USA jtaube1@jhmi.edu.; Bloomberg~Kimmel Institute of Cancer Immunotherapy, Johns Hopkins University SOM, Baltimore, Maryland, USA., Sunshine JC; Bloomberg~Kimmel Institute of Cancer Immunotherapy, Johns Hopkins University SOM, Baltimore, Maryland, USA., Angelo M; Department of Pathology, Stanford University School of Medicine, Palo Alto, California, USA., Akturk G; Merck & Co, Rahway, New Jersey, USA., Eminizer M; Johns Hopkins University, Baltimore, Maryland, USA.; Department of Astronomy and Physics, Johns Hopkins University, Baltimore, Maryland, USA., Engle LL; Bloomberg~Kimmel Institute of Cancer Immunotherapy, Johns Hopkins University SOM, Baltimore, Maryland, USA., Ferreira CS; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany., Gnjatic S; Icahn School of Medicine at Mount Sinai Tisch Cancer Institute, New York, New York, USA., Green B; Bloomberg~Kimmel Institute of Cancer Immunotherapy, Johns Hopkins University SOM, Baltimore, Maryland, USA., Greenbaum S; Department of Pathology, Stanford University School of Medicine, Palo Alto, California, USA., Greenwald NF; Department of Pathology, Stanford University School of Medicine, Palo Alto, California, USA., Hedvat CV; Department of Pathology, Molecular and Cell-based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Hollmann TJ; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Jiménez-Sánchez D; Bloomberg~Kimmel Institute of Cancer Immunotherapy, Johns Hopkins University SOM, Baltimore, Maryland, USA., Korski K; Department of Personalized Healthcare, Data, Analytics and Imaging Group, F Hoffmann-La Roche AG, Basel, Switzerland., Lako A; Dana Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Parra ER; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Rebelatto MC; AstraZeneca, Gaithersburg, Maryland, USA., Rimm DL; Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA., Rodig SJ; Dana Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Rodriguez-Canales J; Daiichi Dankyo, Basking Ridge, New Jersey, USA., Roskes JS; Bloomberg~Kimmel Institute of Cancer Immunotherapy, Johns Hopkins University SOM, Baltimore, Maryland, USA.; Department of Astronomy and Physics, Johns Hopkins University, Baltimore, Maryland, USA., Schalper KA; Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA., Schenck E; AstraZeneca, Gaithersburg, Maryland, USA., Steele KE; SR Pathology LLC, Gaithersburg, Maryland, USA., Surace MJ; AstraZeneca, Gaithersburg, Maryland, USA., Szalay AS; Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University SOM, Baltimore, Maryland, USA.; Bloomberg~Kimmel Institute of Cancer Immunotherapy, Johns Hopkins University SOM, Baltimore, Maryland, USA.; Department of Astronomy and Physics, Johns Hopkins University, Baltimore, Maryland, USA., Tetzlaff MT; Departments of Pathology and Dermatology, University of California San Francisco, San Francisco, California, USA., Wistuba II; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Yearley JH; Merck & Co, Rahway, New Jersey, USA., Bifulco CB; Providence Portland Medical Center, Portland, Oregon, USA. |
| Source: | Journal for immunotherapy of cancer [J Immunother Cancer] 2025 Jan 08; Vol. 13 (1). Date of Electronic Publication: 2025 Jan 08. |
| Publication Type: | Journal Article; Practice Guideline |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
